SA518400501B1 - مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل) - Google Patents
مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل)Info
- Publication number
- SA518400501B1 SA518400501B1 SA518400501A SA518400501A SA518400501B1 SA 518400501 B1 SA518400501 B1 SA 518400501B1 SA 518400501 A SA518400501 A SA 518400501A SA 518400501 A SA518400501 A SA 518400501A SA 518400501 B1 SA518400501 B1 SA 518400501B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- compounds
- disorders
- phenylsulfonyl
- triazol
- diazabicyclo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
يتعلق الاختراع الحالي بـمركبات [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanone بالصيغة العامة (I): حيث يكون كل من R1, R2, R3, R4 و R5 كما عرف هنا، وطرق لتحضير المركبات المذكورة، ومركبات وسيطة مفيدة لتحضير المركبات المذكورة، تراكيب صيدلية وتوليفات تشمل المركبات المذكورة واستخدام المركبات المذكورة لتصنيع التراكيب الصيدلية للمعالجة أو الوقاية من اضطرابات، تحديدا اضطرابات خاصة بأمراض النساء، اضطرابات فرط التكاثر، اضطرابات أيضية، أو اضطرابات التهابية في صورة عامل منفرد أو في توليفة مع مكونات فعالة أخرى.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16171538 | 2016-05-26 | ||
EP16178891 | 2016-07-11 | ||
PCT/EP2017/062359 WO2017202817A1 (en) | 2016-05-26 | 2017-05-23 | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones |
Publications (1)
Publication Number | Publication Date |
---|---|
SA518400501B1 true SA518400501B1 (ar) | 2022-01-16 |
Family
ID=58765840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA518400501A SA518400501B1 (ar) | 2016-05-26 | 2018-11-25 | مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل) |
Country Status (25)
Country | Link |
---|---|
US (1) | US10167293B2 (ar) |
EP (1) | EP3464288B1 (ar) |
JP (1) | JP6918020B2 (ar) |
KR (2) | KR102373202B1 (ar) |
CN (4) | CN109311898B (ar) |
AU (1) | AU2017269871B2 (ar) |
BR (1) | BR112018074381B1 (ar) |
CA (1) | CA3025420A1 (ar) |
CY (1) | CY1123955T1 (ar) |
DK (1) | DK3464288T3 (ar) |
ES (1) | ES2856964T3 (ar) |
HR (1) | HRP20210424T1 (ar) |
HU (1) | HUE053438T2 (ar) |
IL (1) | IL262982B (ar) |
LT (1) | LT3464288T (ar) |
MX (1) | MX2018014541A (ar) |
PE (1) | PE20190204A1 (ar) |
PL (1) | PL3464288T3 (ar) |
RS (1) | RS61520B1 (ar) |
SA (1) | SA518400501B1 (ar) |
SG (1) | SG11201809469QA (ar) |
SI (1) | SI3464288T1 (ar) |
TW (1) | TWI738782B (ar) |
UY (1) | UY37262A (ar) |
WO (1) | WO2017202817A1 (ar) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201825478A (zh) * | 2016-12-19 | 2018-07-16 | 德商拜耳製藥公司 | [4-(苯基磺醯基)哌嗪-1--基](1h-1,2,3-三唑-4-基)甲酮 |
JP7178075B2 (ja) * | 2018-03-22 | 2022-11-25 | 株式会社ユニバーサルコーポレーション | Akr1c3選択的阻害剤及びその用途 |
CN110183455B (zh) * | 2019-06-18 | 2021-04-20 | 中国医科大学 | 氮杂双环[3.2.1]辛-3-酮类化合物及其制备方法与其用途 |
WO2021000862A1 (zh) | 2019-07-01 | 2021-01-07 | 深圳艾欣达伟医药科技有限公司 | Akr1c3抑制剂及医药用途 |
UY38806A (es) * | 2019-08-01 | 2021-02-26 | Novartis Ag | Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1094798A2 (en) | 1998-03-11 | 2001-05-02 | Endorecherche Inc. | INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE |
CN101395134B (zh) * | 2006-03-02 | 2011-08-31 | 安斯泰来制药有限公司 | 17β-羟类固醇脱氢酶5型抑制剂 |
US20070259879A1 (en) | 2006-03-06 | 2007-11-08 | Trimeris, Inc. | Piperazine and piperidine biaryl derivatives |
AU2007231594A1 (en) | 2006-03-23 | 2007-10-04 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
RU2008145871A (ru) | 2006-04-21 | 2010-05-27 | Смитклайн Бичам Корпорейшн (US) | Антагонисты рецептора il-8 |
MX2009000513A (es) * | 2006-07-14 | 2009-03-09 | Genelabs Tech Inc | Agentes antivirales. |
EP2056828A4 (en) | 2006-08-21 | 2010-06-23 | Merck Sharp & Dohme | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS |
CN101772511A (zh) * | 2007-02-16 | 2010-07-07 | 太平洋艾瑞有限公司 | 通过影响粘连蛋白质表达阻止癌细胞的转移和新化合物及其应用 |
WO2009070305A1 (en) * | 2007-11-26 | 2009-06-04 | Eisai E & D Management Co., Ltd. | Method of making imidazoazepinone compounds |
JP5578498B2 (ja) * | 2009-11-10 | 2014-08-27 | 国立大学法人 千葉大学 | 抗癌剤キット及び抗癌剤効果増強剤 |
DE102011083725A1 (de) | 2011-09-29 | 2013-04-04 | Bayer Pharma AG | Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
EP3078374B1 (en) | 2011-10-17 | 2019-06-19 | Vanderbilt University | Indomethacin analogs for the treatment of castrate-resistant prostate cancer |
WO2013142390A1 (en) | 2012-03-21 | 2013-09-26 | Gtx, Inc. | Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors |
PE20150353A1 (es) | 2012-07-10 | 2015-03-28 | Bayer Pharma AG | Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos |
JP6333251B2 (ja) * | 2012-08-16 | 2018-05-30 | バイエル ファーマ アクチエンゲゼルシャフト | 2,3−ベンゾジアゼピン類 |
WO2014039820A1 (en) | 2012-09-07 | 2014-03-13 | Gtx, Inc. | Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors |
AU2014220800A1 (en) * | 2013-02-21 | 2015-08-27 | Bayer Pharma Aktiengesellschaft | Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1 C3) |
JP2015020966A (ja) * | 2013-07-18 | 2015-02-02 | 岐阜市 | Akr1c3阻害剤 |
WO2016037956A1 (en) * | 2014-09-11 | 2016-03-17 | Bayer Pharma Aktiengesellschaft | 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors |
-
2017
- 2017-05-16 US US15/596,383 patent/US10167293B2/en active Active
- 2017-05-22 TW TW106116812A patent/TWI738782B/zh active
- 2017-05-23 KR KR1020187035345A patent/KR102373202B1/ko active IP Right Grant
- 2017-05-23 DK DK17725242.6T patent/DK3464288T3/da active
- 2017-05-23 ES ES17725242T patent/ES2856964T3/es active Active
- 2017-05-23 CN CN201780032131.XA patent/CN109311898B/zh active Active
- 2017-05-23 BR BR112018074381-0A patent/BR112018074381B1/pt active IP Right Grant
- 2017-05-23 MX MX2018014541A patent/MX2018014541A/es unknown
- 2017-05-23 SG SG11201809469QA patent/SG11201809469QA/en unknown
- 2017-05-23 PL PL17725242T patent/PL3464288T3/pl unknown
- 2017-05-23 EP EP17725242.6A patent/EP3464288B1/en active Active
- 2017-05-23 KR KR1020227007577A patent/KR102509150B1/ko active IP Right Grant
- 2017-05-23 HU HUE17725242A patent/HUE053438T2/hu unknown
- 2017-05-23 CN CN202210300841.9A patent/CN114699414A/zh active Pending
- 2017-05-23 WO PCT/EP2017/062359 patent/WO2017202817A1/en unknown
- 2017-05-23 LT LTEP17725242.6T patent/LT3464288T/lt unknown
- 2017-05-23 RS RS20210281A patent/RS61520B1/sr unknown
- 2017-05-23 CA CA3025420A patent/CA3025420A1/en active Pending
- 2017-05-23 CN CN202210300824.5A patent/CN114699413A/zh active Pending
- 2017-05-23 CN CN202210300836.8A patent/CN114702503B/zh active Active
- 2017-05-23 JP JP2018561608A patent/JP6918020B2/ja active Active
- 2017-05-23 SI SI201730609T patent/SI3464288T1/sl unknown
- 2017-05-23 AU AU2017269871A patent/AU2017269871B2/en active Active
- 2017-05-23 PE PE2018003113A patent/PE20190204A1/es unknown
- 2017-05-26 UY UY0001037262A patent/UY37262A/es not_active Application Discontinuation
-
2018
- 2018-11-13 IL IL262982A patent/IL262982B/en unknown
- 2018-11-25 SA SA518400501A patent/SA518400501B1/ar unknown
-
2021
- 2021-03-11 CY CY20211100212T patent/CY1123955T1/el unknown
- 2021-03-12 HR HRP20210424TT patent/HRP20210424T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018550173A1 (en) | Pyrazolopyrimidine derivatives | |
PH12019500932A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
SA518400501B1 (ar) | مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل) | |
PH12019501846A1 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
PH12018502472A1 (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
WO2018077944A3 (en) | 4,5-annulated 1,2,4-triazolones | |
PH12019501034A1 (en) | New anthelmintic quinoline-3-carboxamide derivatives | |
PH12020500257A1 (en) | Quinoline derivatives for treating infections with helminths | |
JO3447B1 (ar) | 2-(مورفولين-4-يل)-7،1-نفثيريدينات | |
PH12019502851A1 (en) | New azaquinoline derivatives | |
PH12020500134A1 (en) | Dihydrooxadiazinones | |
MX2019012803A (es) | Nuevos derivados de pirazol biciclicos. | |
WO2017198341A8 (en) | MACROCYCLIC INDOLE DERIVATIVES | |
PH12020551891A1 (en) | New quinoline derivatives | |
PH12017501133A1 (en) | Pyrazolopyridinamines | |
WO2015150449A3 (en) | Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2 | |
MX2020004981A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
PH12019500808A1 (en) | Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | |
UY37530A (es) | [4-(fenilsulfonil)piperazin-1-il](1h-1,2,3-triazol-4-il)metanonas | |
WO2018114677A3 (en) | [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones | |
EA201892684A1 (ru) | [8-(фенилсульфонил)-3,8-диазабицикло[3.2.1]окт-3-ил](1н-1,2,3-триазол-4-ил)метаноны |